Company Overview
Financial Performance Highlights
Abbott India reported strong financial results for FY26 with revenue from operations reaching ₹6,929 Crores (8.1% growth YoY) and profit after tax of ₹1,552 Crores (9.7% growth YoY). Total income stood at ₹7,217.19 crore. The company achieved EBITDA of ₹2,180 Crores (10.6% growth) and EPS of ₹730.36 (9.7% growth).
Dividend Declaration
The board recommended a final dividend of ₹525 per share plus a special dividend of ₹131 per share (total ₹656 per share, representing 38.1% growth), subject to shareholder approval at the 82nd Annual General Meeting scheduled for August 13, 2026. The dividend absorption amounts to ₹1,393.96 Crores.
Balance Sheet & Cash Flow
Total assets stood at ₹6,501.93 crore with equity of ₹4,774.19 crore. Cash from operating activities was strong at ₹1,319.24 crore, though the company used ₹371.38 crore in investing activities and ₹1,066.12 crore in financing activities (primarily dividend payments).
Business Performance & Leadership
The company maintained leadership positions in multiple therapy areas including #1 in Hepatoprotective and Hormones Therapy, and #4 in Gynaecological, Central Nervous System, Vaccines, and Gastrointestinal Therapy. Key brands Udiliv surpassed ₹700 Crores while Ganaton became the 7th brand to exceed ₹100 Crores. The company launched Extensior (semaglutide) in the GLP-1 segment through partnership with Novo Nordisk.
Corporate Governance & Management Changes
Significant board changes occurred during FY26 with resignations including Swati Dalal (Managing Director) and appointments including Kartik Rajendran as new Managing Director. The board composition includes 9 Directors (1 Executive, 8 Non-Executive including 3 Independent Directors).
Auditor's Report & Compliance
Auditors Walker Chandiok & Co LLP issued an unmodified opinion but noted an exception where the audit trail feature was not enabled at the database level for accounting software. The company paid ₹2,00,000 compounding fee to RBI for foreign investment exceeding sectoral cap and faces a ₹2.40 Crores GST penalty (appeal filed).
Litigations & Contingencies
The company disclosed pending litigations with gross disputed amounts of ₹85.82 crore in income tax and ₹17.12 crore in sales tax matters. Additional contingent liabilities include ₹11.12 crore claim from Government regarding Drugs Prices Equalisation Account.
CSR & ESG Initiatives
CSR spend totaled ₹31.93 Crores with initiatives including upgrading 209 PHCs to Ayushman Arogya Mandirs across 12 states and administering 14,08,406 health screenings. ESG performance included 39.73% energy from renewable sources, 14,600 KL water saved annually, and 279.58 MT CO2 emissions avoided.
Regulatory Compliance & References
The annual report was submitted in compliance with SEBI Listing Regulations 34(1) and 36(1)(a). Prepared in accordance with Indian Accounting Standards (Ind AS) and Companies Act, 2013 requirements.
Capital Structure & Ownership
Authorized share capital is ₹27.50 crore with issued, subscribed & paid-up capital of ₹21.25 crore. Promoter holding stands at 74.99% (Abbott group companies).
Related Party Transactions
Transactions with ultimate holding company (Abbott Laboratories, USA), holding company (Abbott Capital India Ltd., UK), and fellow subsidiaries included payment towards RSU: ₹13.44 crore, remittance of dividend: ₹509.16 crore to holding company, and purchases from fellow subsidiaries: ₹467.07 crore.